Physician profile
Jonathan A Sule
NPI 1932384260
$781.27
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $143.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $147.68 | 2019-2020 | |
| Amgen INC. | $72.02 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $69.90 | 2019 | |
| Adamas Pharmaceuticals, INC. | $60.24 | 2019-2020 | |
| Genentech USA, INC. | $45.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $43.73 | 2019 | |
| Lilly USA, LLC | $35.15 | 2019 | |
| Grifols USA, LLC | $34.13 | 2019-2020 | |
| Acorda Therapeutics, INC | $31.59 | 2019 | |
| Upsher-Smith Laboratories LLC | $30.45 | 2019 | |
| Csl Behring | $29.62 | 2019 | |
| Genzyme Corporation | $25.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.57 | 2019-2020 | |
| Allergan, INC. | $24.34 | 2020 | |
| Eisai INC. | $18.42 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $16.79 | 2020 | |
| Greenwich Biosciences, INC. | $15.71 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.80 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.70 | 2019 | |
| Zyla Life Sciences, INC. | $13.55 | 2019 | |
| Pfizer INC. | $13.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.